首页|胃癌患者血清PG、G-17、IL-6、IL-23、IL-17、TNF-α的检测价值

胃癌患者血清PG、G-17、IL-6、IL-23、IL-17、TNF-α的检测价值

扫码查看
目的 分析胃癌患者血清胃蛋白酶原(PG,PG Ⅰ、PGⅡ)、胃泌素-17(G-17)、白介素(IL)-6、IL-23、IL-17、肿瘤坏死因子-α(TNF-α)的变化及联合检测价值.方法 选择2022年1月-2023年2月于我院就诊的胃癌患者122例为观察组,100例体检健康受试者为对照组,进行平行对照研究.PG Ⅰ、PGⅡ、G-17采用双抗体夹心免疫检测法,IL-6、IL-23、IL-17、TNF-α采用酶联免疫吸附试验(ELISA)检测.比较两组血清PG Ⅰ、PGⅡ、G-17、IL-6、IL-23、IL-17、TNF-α水平,观察组TNM肿瘤分期Ⅰ~Ⅱ期与Ⅲ~Ⅳ期各血清指标的差异.采用受试者工作特征曲线(ROC曲线)分析各血清指标联合检测对胃癌进展(Ⅲ~Ⅳ期)的预测价值.结果 观察组血清PG Ⅰ低于对照组,血清PGⅡ、G-17、IL-6、IL-23、IL-17、TNF-α水平均高于对照组(P<0.05);胃癌患者 TNM Ⅰ~Ⅱ 期血清 PG Ⅰ 高于 TNM Ⅲ~Ⅳ 期,血清 PG Ⅱ、G-17、IL-6、IL-23、IL-17、TNF-α 水平均低于TNM Ⅲ~Ⅳ期(P<0.05).单项血清检查中PG Ⅰ预测胃癌进展AUC较高,为0.976,但各血清指标联合检测预测胃癌进展(Ⅲ~Ⅳ期)的AUC更高,为0.984,特异度98.90%,灵敏度92.60%.结论 胃癌患者PGⅡ、G-17、IL-6、IL-23、IL-17、TNF-α水平呈现高表达,PGⅠ水平呈低表达,不同TNM分期差异显著,可预测胃癌进展,以联合检测效用最高.
Detection Value of Serum PG,G-17,IL-6,IL-23,IL-17 and TNF-α in Patients with Gastric Cancer
Objective To analyze the changes and combined detection value of serum pepsinogen(PG,PG I,PG Ⅱ),gastrin-17(G-17),interleukin(IL)-6,IL-23,IL-17 and tumor necrosis factor-α(TNF-α)in patients with gastric cancer.Methods A total of 122 patients with gastric cancer who were treated in our hospital from January 2022 to February 2023 were selected as the observation group,and 100 healthy subjects were selected as the control group for parallel control study.PGGⅠI,PGⅡ and G-17 were detected by double antibody sandwich immunoassay,and IL-6,IL-23,IL-17 and TNF-α were detected by enzyme-linked immunosorbent assay(ELISA).The levels of serum PG Ⅰ,PGⅡ,G-17,IL-6,IL-23,IL-17 and TNF-αwere compared between the two groups,and the differences of serum indexes between TNM stage Ⅰ-Ⅱ andstage Ⅲ-Ⅳ in the observation group were compared.The receiver operating characteristic curve(ROC curve)was used to analyze the predictive value of combined detection of serum indicators for gastric cancer progression(stage Ⅲ-Ⅳ).Results The serum PGⅠ in the observation group was lower than that in the control group,and the levels of serum PGⅡ,G-17,IL-6,IL-23,IL-17 and TNF-α were higher than those in the control group(P<0.05).The levels of serum PGⅠ in patients with gastric cancer at TNM stage Ⅰ-Ⅱ were higher than those at TNM stage Ⅲ-Ⅳ,and the levels of serum PG Ⅱ,G-17,IL-6,IL-23,IL-17 and TNF-α were lower than those at TNM stage Ⅲ-Ⅳ(P<0.05).In the single serum examination,the AUC of PGI in predicting the progression of gastric cancer was higher,which was 0.976,but the AUC of the combined detection of serum indexes in predicting the progression of gastric cancer(stage Ⅲ-Ⅳ)was higher,which was 0.984,the specificity was 98.90%,and the sensitivity was 92.60%.Conclusion The levels of PGⅡ,G-17,IL-6,IL-23,IL-17 and TNF-α in patients with gastric cancer are highly expressed,and the level of PGⅠ is low.There are significant differences in different TNM stages,which can predict the progression of gastric cancer,and the combined detection has the highest effect.

Gastric cancerPG ⅠPGⅡG-17 ILTNF-α

安钰、李扬、王海、苏成东、高瑞萍、于晓兵

展开 >

宁夏回族自治区人民医院消化内科,宁夏 银川 750021

宁夏回族自治区人民医院内镜中心,宁夏 银川 750021

胃癌 PG PGⅡ G-17 IL TNF-α

2024

医学信息
国家卫生部信息化管理领导小组 中国电子学会中国医药信息学分会 陕西文博生物信息工程研究所

医学信息

影响因子:0.161
ISSN:1006-1959
年,卷(期):2024.37(16)